Northern Trust Corp Buys 120,655 Shares of Xencor, Inc. (NASDAQ:XNCR)

Northern Trust Corp raised its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 19.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 747,152 shares of the biopharmaceutical company's stock after buying an additional 120,655 shares during the quarter. Northern Trust Corp owned about 1.07% of Xencor worth $17,170,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in XNCR. Finepoint Capital LP purchased a new position in Xencor during the fourth quarter valued at $15,167,000. Vanguard Group Inc. raised its position in shares of Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock worth $184,239,000 after purchasing an additional 418,040 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Xencor by 21.3% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company's stock worth $25,102,000 after purchasing an additional 192,080 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Xencor by 12.3% in the 4th quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock worth $37,578,000 after purchasing an additional 179,526 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Xencor by 112.6% in the 4th quarter. Barclays PLC now owns 330,745 shares of the biopharmaceutical company's stock worth $7,600,000 after purchasing an additional 175,177 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Barclays lowered their price target on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research report on Thursday, May 8th. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wells Fargo & Company lowered their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. William Blair assumed coverage on Xencor in a research report on Monday, April 21st. They issued an "outperform" rating for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $29.50.

Insider Buying and Selling at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares in the company, valued at $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.76% of the company's stock.

Xencor Stock Performance

NASDAQ XNCR traded down $0.14 during trading hours on Friday, hitting $8.06. The company's stock had a trading volume of 728,455 shares, compared to its average volume of 646,222. Xencor, Inc. has a 12 month low of $7.16 and a 12 month high of $27.24. The company's 50 day simple moving average is $10.18 and its two-hundred day simple moving average is $17.18. The company has a market cap of $573.49 million, a P/E ratio of -2.52 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The business had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Xencor's quarterly revenue was up 104.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.11) earnings per share. As a group, sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.